Introduction This study aims to assess differences in costs and benefits of treatment strategies for high-risk human epidermal growth factor receptor 2 positive (HER2+) early …
A McBride, K MacDonald… - Journal of Medical …, 2021 - Taylor & Francis
Aims To investigate the cost-efficiency and budget-neutral expanded access of biosimilar intravenous trastuzumab-dkst versus reference intravenous (trastuzumab-IV) and …
S Ailawadhi, A Ravelo, CD Ng, B Shah… - Journal of …, 2024 - becarispublishing.com
Aim: Improved management of chronic lymphocytic leukemia (CLL) has resulted in a growing population of CLL survivors; these patients have a higher risk of developing second …
R Mahtani, N Oestreicher, D Lalla, A Ogbonnaya… - Clinical breast …, 2022 - Elsevier
Introduction: HER2-positive metastatic breast cancer (mBC) is an incurable disease associated with years of chronic therapy and excess cost. HER2-targeted therapies have …
NRM Schwartz, K DeBusk, A Forero-Torres… - Future …, 2021 - Taylor & Francis
Aim: Compare healthcare resource utilization and costs among patients with HER2+ metastatic breast cancer (MBC) with and without central nervous system (CNS) metastases …
HM Chen, JH Chen, SC Chiang, YC Lin, Y Ko - Medicine, 2021 - journals.lww.com
To determine the economic burden of metastatic breast cancer (MBC) in Taiwan, we conducted a national retrospective claim database analysis to evaluate the incremental …
X Cheng, Z Huang, A Pan… - Current Molecular …, 2023 - ingentaconnect.com
Background: Accumulating research has demonstrated that aberrant levels of long noncoding RNAs (LncRNAs) are related to cancer progression. The effects of ORLNC1 in …
M Spanggaard, J Olsen, KF Jensen… - BMC Health Services …, 2022 - Springer
Background Information and knowledge about cost of illness and labour productivity in patients with HER2-positive early-stage and metastatic breast cancer treated with …
JJ Carlson, GF Guzauskas, RA Dann… - Journal of Medical …, 2021 - Taylor & Francis
Abstract Background DiviTum TKa, a blood-based biomarker assay developed to monitor and predict treatment response in hormone receptor positive metastatic breast cancer (HR+ …